Company

Pathos AI

As of the edition of 20 October 2026, Pathos AI runs 3 drugs; it is on route A at 5 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

The records place 2 company names in this family.

  • Rain Oncology Inc: acquired

Drugs by status

StatusCount
Active1
Stopped2
Total3

Where it needs a new molecule

Route A at 5 targets, route B at 0 targets.

Three of its 5 rows, by target and route
TargetRoute
ERBB4 Receptor tyrosine-protein kinase erbB-4Route A
ERBB3 Receptor tyrosine-protein kinase erbB-3Route A
ERBB2 Receptor tyrosine-protein kinase erbB-2Route A

All 5 rows on route A or B

In the product

5 company-target rows on route A or B; 2 are not shown here, and no score is.

Where its trials are

  • Cancer: 7 trials led
  • Lungs and airways: 3 trials led
  • Urinary and reproductive: 3 trials led